Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Moodys
Dow
Express Scripts
Johnson and Johnson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ODM-201

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug ODM-201: Sponsors, patents, clinical trial progress

ODM-201 is an investigational drug.

There have been 41 clinical trials for ODM-201. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Parkinson Disease, and Motor Neuron Disease. The leading clinical trial sponsors are Orion Corporation, Orion Pharma, Bayer, and University of Nottingham.

There are six US patents protecting this investigational drug and eighty international patents.

Recent Clinical Trials for ODM-201
TitleSponsorPhase
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)Sir Mortimer B. Davis - Jewish General HospitalPhase 2
Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label ExtensionOrion Corporation, Orion PharmaPhase 3
Safety and Pharmacokinetics of ODM-209Orion Corporation, Orion PharmaPhase 1/Phase 2

See all ODM-201 clinical trials

Clinical Trial Summary for ODM-201

Top disease conditions for ODM-201
Top clinical trial sponsors for ODM-201

See all ODM-201 clinical trials

US Patents for ODM-201

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ODM-201   See Pricing Carboxamide derivative and its diastereomers in stable crystalline form Orlon Corporation (Espoo, FI)   See Pricing
ODM-201   See Pricing Androgen receptor modulating compounds ORION CORPORATION (Espoo, FI)   See Pricing
ODM-201   See Pricing Process for the preparation of androgen receptor antagonists and intermediates thereof Orion Corporation (Espoo, FI)   See Pricing
ODM-201   See Pricing Androgen receptor modulating carboxamides Orion Corporation (Espoo, FI)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ODM-201

Drugname Country Document Number Estimated Expiration Related US Patent
ODM-201 European Patent Office 3250554 2035-01-30   See Pricing
ODM-201 Japan 2018503662 2035-01-30   See Pricing
ODM-201 World Intellectual Property Organization (WIPO) 2016120530 2035-01-30   See Pricing
ODM-201 Argentina 078793 2029-10-27   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Boehringer Ingelheim
Harvard Business School
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.